Press Releases

CorFlow Infusion SystemTM demonstrated at the recent COMPAMED event

We are delighted to share that, alongside our partners BYTEC Medizintechnik GmbH, the next generation CorFlow Infusion System was demonstrated at the Compamed exhibition. BYTEC has been developing and manufacturing high-tech medical devices in diagnostics, surgery and therapy for more than 30 years. 

The system created a lot of interest from delegates from within Europe as well as from further afield. For further information please contact us!

New ESC Guidelines on the Management of Acute Coronary Syndromes

At the end of August 2023, the European Society of Cardiology released the new guidelines on the management of acute coronary syndromes, combining for the first time the previous STEMI and ACS guidelines. Of note, the experts stated: 

“Microvascular obstruction associated with pPCI represents an unmet clinical need in patients with ACS. Development of therapies for the prevention and treatment of MVO is urgently needed.”

FDA grants “Breakthrough Device Designation” to CorFlow Therapeutics to expedite clinical development and regulatory review of its CoFI (COF-fee) System
AAR, Switzerland–(BUSINESS WIRE)–CorFlow Therapeutics AG today announced that the FDA has designated the company’s CoFI (Controlled Flow Infusion) System as a “Breakthrough Device” with a broad indication-for-use statement: “The CoFI System is indicated for diagnostic assessment of the coronary microcirculation immediately following PCI (“stenting”), and to be a platform for controlled infusion of therapeutic agents into the microcirculation with or without vessel occlusion.”
CorFlow Completes USD 9.7M in Seed Funding
BAAR, Switzerland–(BUSINESS WIRE)–CorFlow Therapeutics AG today announced that the company has completed the 2nd close of its Seed+ financing round.